{"product_id":"cancer-stem-cells-in-glioblastoma-what-they-mean-for-brain-tumor-surgery-recurrence-and-treatment","title":"Cancer Stem Cells in Glioblastoma: What They Mean for Brain Tumor Surgery, Recurrence, and Treatment","description":"\u003cp\u003eThis review explains how cancer stem cells (CSCs) drive the growth, treatment resistance, and near-universal recurrence of glioblastoma, the most common and aggressive primary brain tumor. The authors describe five overlapping tumor microenvironments, called niches, that protect these cells and keep them in a stem-like state. They also show that CSCs spread beyond the tumor margins visible on MRI scans, which helps explain why surgery and standard therapy rarely cure the disease. The review covers CSC biology across other brain tumors as well. The review argues that lasting treatment will require multimodal approaches. These approaches must target both the CSCs themselves and the environments that support the CSCs.\u003c\/p\u003e\n\n\u003ch1\u003eCancer Stem Cells in Glioblastoma: What They Mean for Brain Tumor Surgery, Recurrence, and Treatment\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why Cancer Stem Cells Matter\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#biology\"\u003eCancer Stem Cell Biology in Brain Tumors\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#niches\"\u003eThe Five Tumor Niches That Protect Cancer Stem Cells\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#other-tumors\"\u003eCancer Stem Cells in Other Brain Tumors\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#markers\"\u003eMarkers Used to Identify Cancer Stem Cells\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#models\"\u003eHow Researchers Study Cancer Stem Cells\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations and Open Questions\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eWhat This Means for Patients and Families\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eCancer stem cells in glioblastoma can renew themselves, resist treatment, and spread beyond the tumor margins seen on MRI scans.\u003c\/li\u003e\n\u003cli\u003eFive overlapping niches—perivascular, hypoxic, invasive, immunosuppressive, and extracellular matrix-associated—protect cancer stem cells and support treatment resistance.\u003c\/li\u003e\n\u003cli\u003eMarkers like CD133, CD44, CD15, SOX2, OCT-4, and nestin are not specific to cancer stem cells and do not reliably predict tumor initiation.\u003c\/li\u003e\n\u003cli\u003eLasting treatment will likely require combination approaches that target both cancer stem cells and the supportive microenvironments around them.\u003c\/li\u003e\n\u003cli\u003eThis review is a scientific synthesis, not a clinical trial, and does not replace individualized medical advice from your neuro-oncology team.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why Cancer Stem Cells Matter\u003c\/h2\u003e\n\n\u003cp\u003eCancer stem cells (CSCs) are a small population of tumor cells with stem-like properties. These cells can renew themselves and can change into other cell types. Researchers increasingly believe that CSCs drive tumor initiation, treatment resistance, and relapse.\u003c\/p\u003e\n\n\u003cp\u003eThe CSC hypothesis proposes that many cancers are organized in a hierarchy. A small population of stem-like cells maintains the tumor. These cells promote tumor survival and spread through self-renewal and plasticity (the ability to change state).\u003c\/p\u003e\n\n\u003cp\u003eThis idea has fundamentally shifted how scientists approach cancer. Despite major advances in targeted and cell-based therapies, patients with malignant brain tumors still rarely achieve lasting responses. This gap highlights the need to find and eliminate the specific cell populations responsible for tumor persistence.\u003c\/p\u003e\n\n\u003cp\u003eThe challenge is especially clear in aggressive central nervous system (CNS) tumors. These tumors show high variability between patients and within a single tumor. This variability lets tumors adapt and resist both standard and targeted treatments.\u003c\/p\u003e\n\n\u003cp\u003eOngoing research focuses on the genetic and molecular differences between CSCs and normal stem cells (SCs). The goal is to improve targeted therapies while preserving healthy tissue. This review summarizes current concepts in CSC biology, with a focus on glioblastoma (GBM), and outlines the central role of neuro-oncology in translating these discoveries into treatments.\u003c\/p\u003e\n\n\u003ch2 id=\"biology\"\u003eCancer Stem Cell Biology in Brain Tumors\u003c\/h2\u003e\n\n\u003cp\u003eNeural stem cells are multipotent progenitor cells. Their growth and development are tightly controlled by signals from their surroundings. During brain development, neural stem cells become neurons, astrocytes, and oligodendrocytes. In the adult brain, new neuron formation is largely limited to two regions: the subventricular zone (SVZ) and the subgranular zone of the dentate gyrus.\u003c\/p\u003e\n\n\u003cp\u003eNormal neural stem cells maintain healthy tissue. CSCs, by contrast, support tumor maintenance within a specialized tumor microenvironment (TME). This environment is ruled by disrupted fate control, abnormal niche interactions, and strong stress-response adaptations. These adaptations allow tumors to survive under harsh conditions.\u003c\/p\u003e\n\n\u003cp\u003eNeural stem cells and CSCs share core properties. Both can self-renew, both show multipotency-like differentiation programs, and both use conserved molecular signaling pathways. However, CSCs differ in important ways:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThey lack normal cell-cycle restrictions.\u003c\/li\u003e\n  \u003cli\u003eThey show increased asymmetric division.\u003c\/li\u003e\n  \u003cli\u003eThey can actively suppress antitumor immune responses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese features contribute to the aggressive nature of CSC-driven tumors.\u003c\/p\u003e\n\n\u003cp\u003eThe concept of CSCs dates back to 19th-century observations that tumors may arise from undifferentiated cellular precursors. Later studies in embryonic tumors and teratocarcinomas supported this idea. These studies established that poorly differentiated progenitors can generate diverse malignant cell lineages.\u003c\/p\u003e\n\n\u003cp\u003eClassical CSC theory described a rare, stable, self-renewing, one-way hierarchy. In this model, tumor-propagating capacity persists after cytotoxic stress because CSCs generate rapidly growing progeny with limited differentiation potential. Modern research has refined this framework into a plasticity model. In the plasticity model, CSCs and non-CSCs interconvert dynamically in both directions. This interconversion is shaped by internal regulatory programs and by cues from the microenvironment.\u003c\/p\u003e\n\n\u003cp\u003eCurrent evidence supports a mixed model. In this model, progression and recurrence arise from two sources:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003ePre-existing quiescent (dormant) stem-like cells.\u003c\/li\u003e\n  \u003cli\u003eCSC states induced by therapy or by the niche.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe relative contributions of these two sources appear to depend on anatomical niches and on the treatment context. However, the precise proportions and governing rules remain an active area of investigation.\u003c\/p\u003e\n\n\u003cp\u003eWithin CNS tumors, CSC biology has been studied most extensively in GBM. GBM is the most common and aggressive primary malignant brain tumor. It is defined by marked cellular and molecular heterogeneity and by near-universal recurrence despite multimodal therapy. Glioma stem cells (GSCs) have been implicated in tumor initiation, maintenance, and adaptive treatment resistance. They achieve this through enhanced DNA damage responses, metabolic adaptation, and active remodeling of the tumor microenvironment.\u003c\/p\u003e\n\n\u003ch2 id=\"niches\"\u003eThe Five Tumor Niches That Protect Cancer Stem Cells\u003c\/h2\u003e\n\n\u003cp\u003eThe existence of spatially and functionally specialized niches within the tumor has become a central framework. This framework explains why cytoreductive therapy (treatment that reduces tumor bulk) alone rarely cures malignant CNS tumors. Together, these niches sustain temporary stem-like states, help tumors evade the immune system, and provide resistance to cytotoxic injury through coordinated signaling. The migratory and invasive properties of these cells are another important factor.\u003c\/p\u003e\n\n\u003cp\u003eResearchers have described five niches in the literature:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ePerivascular (around blood vessels)\u003c\/li\u003e\n  \u003cli\u003eHypoxic (low oxygen)\u003c\/li\u003e\n  \u003cli\u003eInvasive\u003c\/li\u003e\n  \u003cli\u003eImmunosuppressive\u003c\/li\u003e\n  \u003cli\u003eExtracellular matrix (ECM)-associated\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eThe Perivascular Niche\u003c\/h3\u003e\n\n\u003cp\u003eIn the perivascular niche, CSCs preserve their stemness through direct cell-to-cell interactions and paracrine signaling (signaling to nearby cells). They interact with endothelial cells (cells that line blood vessels), pericytes, and abnormal vascular remodeling.\u003c\/p\u003e\n\n\u003cp\u003eIn GBM, abnormal blood vessel formation is largely driven by vascular endothelial growth factor (VEGF) secreted from CD133+ CSCs. Endothelial cells and myeloid cells also contribute. Endothelial-derived NOTCH ligands actively strengthen CSC self-renewal. CXCL12–CXCR4 signaling helps keep CSCs within the vascular niche and supports invasion.\u003c\/p\u003e\n\n\u003cp\u003eIL-8 and αvβ8 integrin-mediated TGFβ1 activation are complementary routes. Tumors use these routes to reinforce CSC maintenance, boost immune suppression, and remodel the extracellular matrix. CSCs can also use alternative energy sources. This lets them bypass angiogenic pathways and resist VEGF-targeted anti-angiogenic treatments.\u003c\/p\u003e\n\n\u003ch3\u003eThe Hypoxic Niche\u003c\/h3\u003e\n\n\u003cp\u003eThe hypoxic niche induces stem-like transcriptional states and functional resilience. In GBM, this niche is classically marked by pseudopalisading necrosis. This pattern features hypercellular regions surrounding areas of dead tissue. Necrosis formation is attributed to tumor-driven microvascular thrombosis and blood vessel blockage.\u003c\/p\u003e\n\n\u003cp\u003eRather than reflecting slow tumor growth, oxygen deprivation acts as a powerful regulatory signal. It works through stabilization of hypoxia-inducible factors (HIFs), notably HIF-1α and HIF-2α. These transcriptional states intertwine with STAT3, EGFR\/PI3K\/AKT, IGF1R, IL-8, and alarmin-RAGE signaling. Together, they support CSC tumorigenic capacity, cellular plasticity, migration, invasion, and chemoresistance.\u003c\/p\u003e\n\n\u003cp\u003eHIF-1α enhances CSC self-renewal in part by stabilizing NOTCH intracellular domains. HIF-2α preferentially activates stemness-associated transcriptional states, including NOTCH-related and calcineurin-dependent pathways. Both factors can also promote dedifferentiation toward stem-like states through SOX2-dependent mechanisms. This reinforces the concept that stemness is an adaptive and reversible cellular program.\u003c\/p\u003e\n\n\u003ch3\u003eThe Invasive Niche\u003c\/h3\u003e\n\n\u003cp\u003eThe invasive niche emerges where anatomical pathways meet microenvironmental gradients of oxygen, pH, immune cells, and ECM structure. These gradients shape invasion patterns and select for specialized migratory tumor subpopulations.\u003c\/p\u003e\n\n\u003cp\u003eIn the adult brain, the SVZ is a highly vascularized neurogenic region. Its normal pro-stem-cell conditions also create a permissive hiding place for invasive GSCs. Perivascular and SVZ-associated CXCL12 gradients engage CXCR4 and CXCR7. These signals direct GSC migration along vascular and white-matter tracts, leading to tumor recurrence.\u003c\/p\u003e\n\n\u003cp\u003eInvasion also occurs through coordinated dynamics centered on the Na+–K+–Cl− cotransporter NKCC1. This transporter modulates focal adhesion dynamics and cell contractility. At the tumor edge, GSCs face heightened metabolic and oxidative stress. Fluctuating oxygen and nutrient gradients promote selection and plasticity for stem-like states.\u003c\/p\u003e\n\n\u003cp\u003eIntegrins α6β1, αvβ3, αvβ5, and αvβ6 mediate adhesion to laminin-rich and vitronectin-rich matrices. FAK-Src dual kinase complexes activate downstream effectors that regulate motility, proliferation, and survival. Across multiple models, WNT\/β-catenin, TGFβ-SMAD, and NOTCH pathways interlock with HIF signaling. This network supports an epithelial–mesenchymal-like plasticity that enables invasion.\u003c\/p\u003e\n\n\u003cp\u003eClinically, this translates into diffuse GSC infiltration beyond MRI tumor boundaries. This infiltration undermines complete surgical resection attempts and contributes to recurrence despite adjuvant therapy.\u003c\/p\u003e\n\n\u003ch3\u003eThe Immunosuppressive Niche\u003c\/h3\u003e\n\n\u003cp\u003eThe immunosuppressive niche arises from vascular dysfunction and tissue damage signals. Combined with hypoxia and necrosis, these signals reshape local immunity. They stimulate infiltration of regulatory T-cells (Tregs) and recruitment of bone-marrow-derived monocytes. These monocytes differentiate into tumor-associated macrophages (TAMs). Granulocytes also arrive and mature into tumor-associated neutrophils (TANs).\u003c\/p\u003e\n\n\u003cp\u003eThis immune context suppresses antigen presentation and weakens T-cell effector activity. It does so through convergent signaling via VEGF, macrophage colony-stimulating factor 1 (CSF1), CXCL12, IL-1β, IL-6\/STAT3, TGF-β, and immune checkpoint pathways such as PD-1\/PD-L1.\u003c\/p\u003e\n\n\u003cp\u003eFunctionally, this niche protects CSCs from chemoradiation. It maintains CSCs in a relatively quiescent state and supports their later re-entry into the cell cycle. This process facilitates tumor regrowth and relapse.\u003c\/p\u003e\n\n\u003ch3\u003eThe Extracellular Matrix-Associated Niche\u003c\/h3\u003e\n\n\u003cp\u003eThe pathological ECM niche built by the tumor provides a dynamic, instructive scaffold. This scaffold helps stabilize CSCs through combined biochemical and biomechanical cues.\u003c\/p\u003e\n\n\u003cp\u003eThe glycoprotein tenascin-C is a central component. It accumulates in invasive and perivascular regions, boosting angiogenesis and tumor cell proliferation. Brain-derived chondroitin sulfate proteoglycans uphold infiltrative behavior and reinforce tumor-initiating capacity.\u003c\/p\u003e\n\n\u003cp\u003eTAM secretion of TGF-β leads to ECM remodeling through metalloproteinases MMP2\/9 and ADAMTS proteases. This remodeling amplifies EGFR activity at invasive fronts. In parallel, integrin signaling and increased matrix stiffness act together to activate the YAP\/TAZ pathway. This activation stabilizes CSCs and their migratory potential.\u003c\/p\u003e\n\n\u003ch3\u003eHow the Niches Work Together\u003c\/h3\u003e\n\n\u003cp\u003eThese five categories overlap and should not be viewed as mutually exclusive. Despite high vessel density, the chaotic nature of GBM vasculature creates intermittent blood flow. This produces hypoxic gradients within the tumor. Immune cells and stromal elements integrate across microdomains. They upregulate the CXCL12–CXCR4 signaling axis. In this way, the niches adapt to form an interactive migratory front and an immunomodulatory sanctuary for CSCs.\u003c\/p\u003e\n\n\u003ch2 id=\"other-tumors\"\u003eCancer Stem Cells in Other Brain Tumors\u003c\/h2\u003e\n\n\u003cp\u003eThe CSC concept extends beyond GBM and appears broadly applicable to CNS tumors. Researchers have reported stem-like populations across adult and pediatric tumors. These include meningiomas, pituitary adenomas, schwannomas, oligodendrogliomas, ependymomas, and medulloblastomas. The depth of experimental validation varies among these tumors. Still, accumulating evidence suggests that stem-like compartments may contribute to tumor initiation and recurrence.\u003c\/p\u003e\n\n\u003ch3\u003eMeningiomas\u003c\/h3\u003e\n\n\u003cp\u003eMeningiomas are primary intracranial tumors that are typically benign. The evidence for distinct meningioma stem cells (MgSCs) remains less robust than for GSCs. Nonetheless, developing data suggest the presence of stem-like populations. These populations express markers shared with GSCs, such as CD133, OCT-4, SOX2, and nestin.\u003c\/p\u003e\n\n\u003cp\u003eTranscriptomic and signaling analyses further suggest that MgSC-associated signaling contributes to aggressive features and recurrence. CXCL11 and CXCL12 have been implicated in malignant phenotypes. Clinically, meningioma management is strongly influenced by tumor location. Convexity tumors often allow wider surgical margins. Skull base tumors frequently touch or encase critical neurovascular structures, which limits the extent of resection.\u003c\/p\u003e\n\n\u003cp\u003eWithin these anatomical constraints, residual microscopic disease may persist after surgery. MgSCs residing in protective niches may also persist and contribute to recurrence. This risk is particularly relevant in higher-grade tumors or tumors that are surgically inaccessible.\u003c\/p\u003e\n\n\u003ch3\u003ePituitary Neuroendocrine Tumors\u003c\/h3\u003e\n\n\u003cp\u003ePituitary neuroendocrine tumors (PitNETs) arise from anterior pituitary cells. They are usually benign but can be locally invasive, recurrent, and treatment-refractory in a small subset of patients. As in meningiomas, there is limited evidence for true CSCs in PitNETs.\u003c\/p\u003e\n\n\u003cp\u003eResearchers have identified subpopulations expressing OCT-4, SOX2, CD133, and nestin in laboratory cultures and in xenografts (human tumor tissue grown in animals). These cells show proliferative capacity and multilineage differentiation toward hormone-producing pituitary cells. This suggests a potential role in local infiltration.\u003c\/p\u003e\n\n\u003cp\u003eIn an estradiol-benzoate-induced PitNET rat model, CSC markers were preferentially expressed in the adenoparenchyma rather than in the marginal zone. This contrasts with their distribution in normal pituitary tissue. Early evidence suggests that PitNET CSCs may migrate from marginal zones to form adenoparenchymal niches during early tumor development.\u003c\/p\u003e\n\n\u003ch3\u003eMedulloblastoma\u003c\/h3\u003e\n\n\u003cp\u003eMedulloblastoma is the most common malignant pediatric brain tumor. CSC-like cells expressing CD133, SOX2, and nestin have been linked to tumor propagation and resistance. Key developmental pathways, including SHH, WNT, NOTCH, and MYC, play central roles in maintaining stemness.\u003c\/p\u003e\n\n\u003cp\u003eA study using orthotopic medulloblastoma xenografts (tumors grown in the brain of an animal model) demonstrated that CD133+ tumor cells can form neurospheres. These cells also participate in multilineage differentiation even after several passages. This suggests that CSCs exist in some medulloblastoma variants.\u003c\/p\u003e\n\n\u003ch3\u003eEpendymomas\u003c\/h3\u003e\n\n\u003cp\u003eEpendymomas, particularly posterior fossa subtypes, also harbor stem-like, radial glia-like compartments. These compartments are shaped by profound epigenetic dysregulation. TGF-β and WNT\/β-catenin transcriptional states correlate with recurrence and poor clinical outcomes.\u003c\/p\u003e\n\n\u003cp\u003eSingle-cell analyses of all major ependymoma groups suggest three fates for ependymoma stem-like cell differentiation:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eEpendymal-like cells\u003c\/li\u003e\n  \u003cli\u003eGlial-progenitor-like cells\u003c\/li\u003e\n  \u003cli\u003eNeuronal-precursor-like cells\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe tumors with the poorest prognosis mainly contained undifferentiated cells.\u003c\/p\u003e\n\n\u003ch3\u003eOligodendrogliomas\u003c\/h3\u003e\n\n\u003cp\u003eAcross IDH-mutant oligodendrogliomas, progenitor-like oligodendrocyte precursor cell states use IDH-dependent methylation and chromatin changes. These changes stall differentiation and enable plastic progression toward more proliferative progenitor states. Although oligodendrocyte precursor cells have distinct origins from GSCs, a single-cell study of oligodendrogliomas revealed several overlapping functions that contribute to proliferative capacity.\u003c\/p\u003e\n\n\u003ch3\u003eSchwannomas\u003c\/h3\u003e\n\n\u003cp\u003eSchwannomas are benign neural crest-derived tumors. They have been shown to express embryonic stem cell-like markers, including CD133, OCT-4, and SOX2. This is consistent with a stem-like compartment. The contribution of CSCs to schwannoma growth and recurrence is an important area for future functional work.\u003c\/p\u003e\n\n\u003ch3\u003eCommon Themes Across Brain Tumors\u003c\/h3\u003e\n\n\u003cp\u003eDespite broad evidence for stem-like features in many solid tumors, the extent of strict hierarchical organization differs across CNS tumors. The degree of CSC dependence also differs, even between molecular subtypes within a given tumor type. Nonetheless, recurrent themes emerge:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eActivation of conserved developmental pathways\u003c\/li\u003e\n  \u003cli\u003eEpigenetic plasticity\u003c\/li\u003e\n  \u003cli\u003eNiche-mediated protection from therapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"markers\"\u003eMarkers Used to Identify Cancer Stem Cells\u003c\/h2\u003e\n\n\u003cp\u003eResearchers have proposed multiple potential biomarkers for GSC identification. These include CD133, CD44, CD15, SOX2, OCT-4, and nestin. However, these markers are neither universally expressed nor specific to GSCs. There is substantial overlap across normal neural stem cells and other tumor populations.\u003c\/p\u003e\n\n\u003cp\u003eA persistent controversy is that marker-defined CSC fractions shift with culture conditions, microenvironmental cues, and therapy-induced stress. Marker positivity does not consistently align with tumor-initiating capacity. As a result, purely marker-based CSC estimates are difficult to interpret and hard to compare across studies or tumor types. Modern efforts therefore increasingly combine marker-based enrichment with functional assays and single-cell profiling.\u003c\/p\u003e\n\n\u003cp\u003eSingle-cell RNA sequencing has been used to define transcriptional axes associated with classical and mesenchymal stem-like cellular states. These include MEOX2-NOTCH and SRGN-NFκB programs. With so many regulatory signals involved, knowledge of key factors and behaviors in CSC molecular profiles is essential for understanding their highly heterogeneous nature.\u003c\/p\u003e\n\n\u003ch2 id=\"models\"\u003eHow Researchers Study Cancer Stem Cells\u003c\/h2\u003e\n\n\u003cp\u003eStem cell-based tumor models are needed to preserve the biological features that drive tumor persistence. These models retain tumor characteristics including propagation, cellular plasticity, and clinically relevant heterogeneity. By maintaining these dynamic and diverse states, the models provide an essential framework to study CSC biology and microenvironmental dependencies. They enable researchers to identify niche-derived cues that sustain CSC survival and tumor regeneration across ex vivo (outside the body) and in vivo (inside the body) approaches.\u003c\/p\u003e\n\n\u003ch3\u003eEx Vivo Models\u003c\/h3\u003e\n\n\u003cp\u003eEx vivo stem cell-based models allow controlled manipulation of niche-associated variables. This allows researchers to understand the mechanisms of CSC regulation.\u003c\/p\u003e\n\n\u003cp\u003eHistorically, neuro-oncology research has relied heavily on glioma-derived immortalized cell lines. These are experimentally convenient, but their growth as two-dimensional (2D) monolayers limits cellular heterogeneity and microenvironmental gradients. Furthermore, prolonged passaging often leads to clonal drift. This yields models that progressively diverge from the original tumors.\u003c\/p\u003e\n\n\u003cp\u003eNext-generation stem-like cultures incorporate ECM substrates, microfluidic gradient systems, and multicellular co-cultures. These approaches partially replicate structural and biochemical niche features. They also address the progressive divergence seen in progenitor cell lines.\u003c\/p\u003e\n\n\u003cp\u003eGiven the central role of three-dimensional (3D) architecture in glioma aggressiveness, 3D tumor models represent a major advance in neuro-oncology research. Among these models, patient-derived tumor organoids (PDTOs) and neurosphere cultures are established directly from surgical specimens. They are maintained under serum-free conditions. These models can retain aspects of intratumoral heterogeneity linked to stemness. In this way, they mimic clinically relevant variability in treatment responses.\u003c\/p\u003e\n\n\u003cp\u003ePDTOs preserve native cell-to-cell interactions. In some cases, they maintain infiltrating immune or stromal elements from the original tumor. Organoids often show selective radiosensitivity. Differentiated tumor cells are preferentially eliminated while adjacent GSCs persist. This mirrors clinical patterns of incomplete eradication and relapse.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, the cerebral organoid glioma (GLICO) model provides a human neural-like scaffold. In this model, GSCs infiltrate in patterns that closely resemble disease in living organisms. They form tumor foci with microtube-associated networks implicated in infiltration.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis research reframes how doctors and scientists think about treating glioblastoma and other CNS tumors. The key message is that lasting therapeutic response will likely require multimodal approaches. Treatment must target both CSC-intrinsic pathways and the supportive microenvironments around them.\u003c\/p\u003e\n\n\u003cp\u003eSeveral specific implications stand out:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCSCs extend beyond radiographic margins.\u003c\/strong\u003e CSCs populate peritumoral regions beyond the contrast-enhancing tumor margins seen on imaging. This provides a biological basis for near-universal recurrence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLongitudinal outcomes depend on CSC eradication.\u003c\/strong\u003e Long-term therapeutic outcomes are increasingly dictated by the success or failure of total CSC eradication.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurgery must balance two goals.\u003c\/strong\u003e The findings highlight the need for function-preserving maximal resection. Surgeons aim to remove as much tumor as possible while protecting healthy brain function.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSingle-target therapies are unlikely to succeed.\u003c\/strong\u003e Because CSCs use multiple resistance mechanisms and multiple protective niches, sustained response will likely require combination approaches.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe five niches cooperate to enforce stemness, metabolic adaptability, immune evasion, and phenotypic plasticity. This cooperation enables CSC persistence despite maximal surgical resection and standard-of-care therapy. Advances in multiparametric imaging, stem cell-based ex vivo and in vivo models, and single-cell and spatial profiling have refined insight into CSC heterogeneity, niche dependence, and treatment resistance.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations and Open Questions\u003c\/h2\u003e\n\n\u003cp\u003eThe review identifies several important limitations and unresolved questions in the field.\u003c\/p\u003e\n\n\u003cp\u003eFirst, the precise proportions and governing rules of CSC dynamics remain an active area of investigation. Researchers do not yet know exactly how much recurrence comes from pre-existing dormant stem-like cells versus therapy-induced or niche-induced CSC states.\u003c\/p\u003e\n\n\u003cp\u003eSecond, CSC markers are not reliable on their own. Markers such as CD133, CD44, CD15, SOX2, OCT-4, and nestin are neither universally expressed nor specific to GSCs. Marker positivity does not consistently align with tumor-initiating capacity. This makes purely marker-based CSC estimates difficult to interpret and compare across studies.\u003c\/p\u003e\n\n\u003cp\u003eThird, the strength of evidence varies widely across tumor types. Evidence for CSCs is most extensive in glioblastoma. For meningiomas and pituitary neuroendocrine tumors, evidence for true CSCs remains limited. For schwannomas, the functional contribution of CSCs to growth and recurrence is not yet established.\u003c\/p\u003e\n\n\u003cp\u003eFourth, the extent of strict hierarchical organization and the degree of CSC dependence differ across CNS tumors. They even differ between molecular subtypes within a given tumor type.\u003c\/p\u003e\n\n\u003cp\u003eFifth, the five niches overlap and should not be viewed as mutually exclusive. This overlap makes it difficult to study each niche in isolation.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eWhat This Means for Patients and Families\u003c\/h2\u003e\n\n\u003cp\u003eThis review is a scientific synthesis, not a clinical trial. It does not test a new drug or report patient outcomes from a new treatment. However, its findings offer several practical takeaways for patients and families navigating a brain tumor diagnosis.\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand why recurrence is common.\u003c\/strong\u003e In glioblastoma, cancer stem cells spread beyond the tumor margins visible on MRI scans. This is a biological reason why the tumor so often returns, even after successful-looking surgery and standard therapy. Recurrence is not a failure of the patient or the surgical team.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about the extent of resection.\u003c\/strong\u003e The review supports function-preserving maximal resection. This means removing as much tumor as safely possible while protecting brain function. Patients can ask their surgical team how the planned resection balances tumor removal against neurological risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExpect combination approaches.\u003c\/strong\u003e Because CSCs use multiple resistance mechanisms and hide in multiple protective niches, single-target therapies are unlikely to produce lasting responses. Patients may be offered combinations of treatments, and this reflects the biology described in this review.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about clinical trials.\u003c\/strong\u003e The review highlights the need for multimodal therapies that target both CSCs and their supportive microenvironments. Clinical trials are where these new combination strategies are tested.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRecognize that research is advancing.\u003c\/strong\u003e New imaging methods, stem cell-based laboratory models, and single-cell and spatial profiling techniques are refining how researchers understand CSC heterogeneity and treatment resistance. These tools are building the foundation for future therapies.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003ePatients should discuss all treatment decisions with their neuro-oncology team. The findings in this review describe the biology behind the disease. They do not replace individualized medical advice.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhy does glioblastoma often come back after surgery and treatment?\u003c\/h3\u003e\n\u003cp\u003eCancer stem cells spread beyond the tumor margins visible on MRI scans. This means microscopic tumor cells remain after surgery and standard therapy. These cells can renew themselves, resist treatment, and hide in protective environments called niches. Recurrence is not a failure of the patient or the surgical team; it reflects the biology of the disease.\u003c\/p\u003e\n\u003ch3\u003eWhat are the five niches that protect cancer stem cells?\u003c\/h3\u003e\n\u003cp\u003eThe five niches are perivascular (around blood vessels), hypoxic (low oxygen), invasive, immunosuppressive, and extracellular matrix-associated. These overlapping environments keep cancer stem cells in a stem-like state, help them evade the immune system, and provide resistance to treatment. They work together to support tumor survival and regrowth.\u003c\/p\u003e\n\u003ch3\u003eWhat does it mean if my tumor has cancer stem cell markers like CD133?\u003c\/h3\u003e\n\u003cp\u003eMarkers such as CD133, CD44, CD15, SOX2, OCT-4, and nestin are used to identify cancer stem cells, but they are not specific. They can appear on normal neural stem cells and other tumor cells. Marker positivity does not always mean a cell can start a tumor. Researchers now combine markers with functional tests and single-cell profiling for clearer results.\u003c\/p\u003e\n\u003ch3\u003eWhy are single-target therapies unlikely to work for glioblastoma?\u003c\/h3\u003e\n\u003cp\u003eCancer stem cells use multiple resistance mechanisms and hide in several protective niches. A therapy that targets only one pathway or one niche may leave other cancer stem cells untouched. Lasting treatment will likely require combination approaches that target both the cancer stem cells themselves and the supportive environments around them.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my surgeon about removing my brain tumor?\u003c\/h3\u003e\n\u003cp\u003eYou can ask how the planned resection balances removing as much tumor as safely possible against protecting healthy brain function. This is called function-preserving maximal resection. Because cancer stem cells can spread beyond the visible tumor margins, complete removal is difficult. Your surgical team can explain the goals and risks for your specific case.\u003c\/p\u003e\n\u003ch3\u003eAre clinical trials important for brain tumor treatment?\u003c\/h3\u003e\n\u003cp\u003eClinical trials are where new combination strategies that target cancer stem cells and their supportive microenvironments are tested. Because single-target therapies are unlikely to produce lasting responses, trials of multimodal approaches are needed. You can ask your neuro-oncology team whether a clinical trial is appropriate for your situation.\u003c\/p\u003e\n\u003ch3\u003eI was just diagnosed with glioblastoma — when should I seek a second opinion about surgery and treatment?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is worth considering at diagnosis, before surgery, and whenever a treatment plan is proposed. Cancer stem cells spread beyond the tumor margins visible on MRI scans, which is a biological reason glioblastoma so often returns even after successful-looking surgery and standard therapy. Because these cells use multiple resistance mechanisms and hide in five overlapping protective niches, single-target therapies are unlikely to produce lasting responses. A second opinion can review imaging, pathology, and whether the planned resection balances tumor removal against neurological risk. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Neuro-Oncological Perspectives on Cancer Stem Cell Biology in Glioblastoma: Implications for Resection, Recurrence, Targeted Therapy, and Other CNS Tumors.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Salmeron-Moreno K, Papisetty K, Kim CD, McCaffery T, Kashlan R, Theodore J, Kim JM, Buclez J, Duggireddy H, Maldonado J, Guerrero-Cázares H, Pradilla G, Garzon-Muvdi T.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthor affiliations:\u003c\/strong\u003e Department of Neurological Surgery, Emory University, Atlanta, GA, USA; Neurosurgery Department, Mayo Clinic, Jacksonville, FL, USA\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Cells, 2026, volume 15, article 413\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication dates:\u003c\/strong\u003e Received 6 February 2026; Revised 24 February 2026; Accepted 25 February 2026; Published 27 February 2026\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e https:\/\/doi.org\/10.3390\/cells15050413\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eArticle type:\u003c\/strong\u003e Review article, open access under the Creative Commons Attribution (CC BY) license\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace consultation with a qualified medical professional.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47816790900892,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0599\/5449\/5644\/files\/ddn-medical-article-cancer-stem-cells-in-glioblastoma-what-they-mean-for-brain-tumor-surgery-recurrence-and-treatment-hero.png?v=1792909249","url":"https:\/\/diagnosticdetectives.com\/it\/products\/cancer-stem-cells-in-glioblastoma-what-they-mean-for-brain-tumor-surgery-recurrence-and-treatment","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}